Q2 EPS Estimates for Vor Biopharma Lifted by HC Wainwright

Vor Biopharma Inc. (NASDAQ:VOR) – Stock analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Vor Biopharma in a research note issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.67) for the quarter, up from their prior estimate of ($0.94). HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Vor Biopharma’s Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.88) EPS, FY2027 earnings at ($2.78) EPS, FY2028 earnings at ($1.67) EPS, FY2029 earnings at $1.86 EPS and FY2030 earnings at $4.27 EPS.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter.

A number of other research analysts have also weighed in on the stock. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Wedbush raised their price target on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $14.13 on Wednesday. Vor Biopharma has a twelve month low of $3.30 and a twelve month high of $65.80. The firm’s 50-day moving average price is $15.08 and its 200 day moving average price is $13.96.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of Vor Biopharma stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. This trade represents a 6.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 3,002,903 shares of company stock valued at $49,412,176. 0.45% of the stock is currently owned by company insiders.

Institutional Trading of Vor Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. Fcpm Iii Services B.V. acquired a new position in shares of Vor Biopharma in the third quarter worth $18,496,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the second quarter worth $66,000. Goldman Sachs Group Inc. increased its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. Bank of America Corp DE increased its position in shares of Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after acquiring an additional 112,496 shares during the period. Finally, Sei Investments Co. purchased a new stake in shares of Vor Biopharma during the first quarter worth $245,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).